key: cord-0690862-l0fv7kis authors: Ugarte-Gil, Manuel Francisco; Alarcón, Graciela S; Izadi, Zara; Duarte-García, Ali; Reátegui-Sokolova, Cristina; Clarke, Ann Elaine; Wise, Leanna; Pons-Estel, Guillermo J; Santos, Maria Jose; Bernatsky, Sasha; Ribeiro, Sandra Lúcia Euzébio; Al Emadi, Samar; Sparks, Jeffrey A; Hsu, Tiffany Y -T; Patel, Naomi J; Gilbert, Emily L; Valenzuela-Almada, Maria O; Jönsen, Andreas; Landolfi, Gianpiero; Fredi, Micaela; Goulenok, Tiphaine; Devaux, Mathilde; Mariette, Xavier; Queyrel, Viviane; Romão, Vasco C; Sequeira, Graca; Hasseli, Rebecca; Hoyer, Bimba; Voll, Reinhard E; Specker, Christof; Baez, Roberto; Castro-Coello, Vanessa; Maldonado Ficco, Hernan; Reis Neto, Edgard Torres; Ferreira, Gilda Aparecida Aparecida; Monticielo, Odirlei Andre André; Sirotich, Emily; Liew, Jean; Hausmann, Jonathan; Sufka, Paul; Grainger, Rebecca; Bhana, Suleman; Costello, Wendy; Wallace, Zachary S; Jacobsohn, Lindsay; Taylor, Tiffany; Ja, Clairissa; Strangfeld, Anja; Mateus, Elsa F; Hyrich, Kimme L; Carmona, Loreto; Lawson-Tovey, Saskia; Kearsley-Fleet, Lianne; Schäfer, Martin; Machado, Pedro M; Robinson, Philip C; Gianfrancesco, Milena; Yazdany, Jinoos title: Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance date: 2022-02-15 journal: Ann Rheum Dis DOI: 10.1136/annrheumdis-2021-221636 sha: 922f6114bbcba4a1411c689abc19d84cc68fb8ef doc_id: 690862 cord_uid: l0fv7kis AIM: To determine characteristics associated with more severe outcomes in a global registry of people with systemic lupus erythematosus (SLE) and COVID-19. METHODS: People with SLE and COVID-19 reported in the COVID-19 Global Rheumatology Alliance registry from March 2020 to June 2021 were included. The ordinal outcome was defined as: (1) not hospitalised, (2) hospitalised with no oxygenation, (3) hospitalised with any ventilation or oxygenation and (4) death. A multivariable ordinal logistic regression model was constructed to assess the relationship between COVID-19 severity and demographic characteristics, comorbidities, medications and disease activity. RESULTS: A total of 1606 people with SLE were included. In the multivariable model, older age (OR 1.03, 95% CI 1.02 to 1.04), male sex (1.50, 1.01 to 2.23), prednisone dose (1–5 mg/day 1.86, 1.20 to 2.66, 6–9 mg/day 2.47, 1.24 to 4.86 and ≥10 mg/day 1.95, 1.27 to 2.99), no current treatment (1.80, 1.17 to 2.75), comorbidities (eg, kidney disease 3.51, 2.42 to 5.09, cardiovascular disease/hypertension 1.69, 1.25 to 2.29) and moderate or high SLE disease activity (vs remission; 1.61, 1.02 to 2.54 and 3.94, 2.11 to 7.34, respectively) were associated with more severe outcomes. In age-adjusted and sex-adjusted models, mycophenolate, rituximab and cyclophosphamide were associated with worse outcomes compared with hydroxychloroquine; outcomes were more favourable with methotrexate and belimumab. CONCLUSIONS: More severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE. Patients using glucocorticoids also experienced more severe outcomes. During the COVID-19 pandemic, individuals with systemic lupus erythematosus (SLE) have been of particular concern. SLE disproportionately impacts populations most severely affected by COVID-19, including those from non-white racial and ethnic groups, and those with low socioeconomic status. 1 Moreover, individuals with SLE are often heavily immunosuppressed and have a high comorbidity burden with multiple risk factors for more severe COVID-19. Although previous analyses have evaluated outcomes of infection with SARS-Cov-2 in rheumatic diseases as a group, data on individuals with SLE are limited, and it remains unclear which risk factors are associated with worse COVID-19 outcomes in this population. Data from the COVID-19 Global Rheumatology Alliance (C19-GRA) registry, a large physician reported registry of individuals with rheumatic diseases and COVID-19, suggest that those with moderate or high disease activity, as well as those receiving specific medications, including moderate or high doses of prednisone, rituximab, immunosuppressive drugs (ie, mycophenolate mofetil/mycophenolic acid (MMF), tacrolimus, azathioprine and cyclophosphamide) compared with a reference group of individuals receiving methotrexate have poorer outcomes. 2 Furthermore, in an analysis of patients in the C19-GRA registry with rheumatoid arthritis (RA), treatment with rituximab or Janus Kinase (JAK) inhibitors was associated with poorer outcomes compared with treatment with tumour necrosis factor inhibitors. 3 However, medications associated with more severe COVID-19 outcomes in SLE have not been extensively examined. OpenSAFELY, a large analysis of primary care records of >17 million adults linked to 10 926 COVID-19-related deaths reported that after adjustment for a wide variety of factors such as demographic characteristics and comorbidities, those with autoimmune disease (SLE, RA or psoriasis as a group) had a higher risk of mortality, but this study did not adjust for medication use, nor did it evaluate SLE as a discrete or separate disease. 4 Several case series or single-centre/country studies suggest that some individuals with SLE can have a severe disease course, but the small size of these studies has precluded a comprehensive analysis of risk factors for poor COVID-19 outcomes. [5] [6] [7] [8] [9] [10] We used the C19-GRA registry to identify sociodemographic and clinical factors associated with more severe COVID-19 outcomes in individuals with SLE. Subjetcs with rheumatic disease and COVID-19 from the C19-GRA registry and European Alliance of Associations for Rheumatology (EULAR) COVID-19 registry were included in the analyses, which covered the period from 12 March 2020 to 1 June 2021. Data entry portals include one limited to European countries ( eular. org/ eular_ covid19_ database. cfm; hosted by The University of Manchester, UK) and a second for all other countries ( rheum-covid. org/ provider-global/; hosted by the University of California, San Francisco (UCSF), California, USA). 11 12 Cases are entered into these registries by their treating clinicians. This study includes all individuals from these registries with SLE diagnosed with COVID-19 by 1 June 2021. Prior studies using C19-GRA and EULAR databases have included some individuals also reported in this study, 2 13 14 but the number of individuals in this analysis is significantly higher than reported in previous publications. Data quality was assessed by the data coordinating centres at UCSF and the University of Manchester and included procedures to identify and remove any duplicate cases. We used an ordinal severity outcome in the analyses, with mutually exclusive categories including: (1) not hospitalised, (2) hospitalised with no oxygenation, (3) hospitalised with any ventilation or oxygenation or (4) death. These outcomes were chosen so that the analyses could reflect the full spectrum of disease associated with COVID-19 and are analogous to outcome measures used in many trials evaluating COVID-19 therapeutics. Only the highest severity level of the outcome occurring during the patient's disease course was included, and all individuals were required to have a resolved clinical course. Covariates included demographic characteristics, including age, sex and region (Europe, the USA and Canada, Latin America and other), as well as clinical characteristics, including number of comorbidities (including lung, liver or neurological diseases, cancer, diabetes, obesity, among others), specific comorbidities (chronic renal insufficiency or end-stage renal disease and hypertension or cardiovascular disease), disease activity (assessed by a physician global assessment categorised as remission, low, moderate or high), dose of glucocorticoids (GCs; entered as daily oral prednisone equivalents) and use of immunosuppressive or immunomodulating medications. Additionally, the date of the case report was analysed in three time periods: 24 March 2020 to 15 June 2020, 16 June 2020 to 30 September 2020 and 1 October 2020 to 1 June 2021. The first period ended at the release of the RECOVERY study, which changed COVID-19 treatment protocols to incorporate GCs. 15 The second cut-off was based on the beginning of the second wave in many countries around the world. Medications taken by patients prior to COVID-19 were categorised as: conventional synthetic drugs (antimalarials (hydroxychloroquine, chloroquine), conventional disease-modifying monotherapies generally considered to represent less intensive immunosuppression (sulfasalazine, methotrexate and leflunomide), conventional disease-modifying monotherapies with more intense immunosuppressive drugs (MMF, tacrolimus, cyclophosphamide, ciclosporin, azathioprine)); biologics (abatacept, belimumab, rituximab, interleukin (IL)-6 inhibitors, IL-12/ IL-23 inhibitors, IL-17 inhibitors, tumour necrosis factor inhibitors (anti-TNF)) and targeted synthetic drugs, specifically JAK inhibitors and GCs. In analyses, we divided medications into five groups: no SLE medications, antimalarial only, conventional disease-modifying monotherapies generally considered to represent less intensive immunosuppression (sulfasalazine, methotrexate and leflunomide), conventional disease-modifying What is already known about this subject? ► Demographic factors as well as comorbidities have been associated with poorer COVID-19 outcomes in the general population. ► The COVID-19 Global Rheumatology Alliance has reported glucocorticoid dose (≥10 mg/day), some immunosuppressive drugs and disease activity as predictors of poorer COVID-19 outcomes in individuals with different rheumatic diseases. What does this study add? ► More severe COVID-19 outcomes in individuals with systemic lupus erythematosus (SLE) are mainly driven by demographic factors, comorbidities and untreated or active SLE. ► Individuals using glucocorticoids (even low dose) experienced more severe outcomes. How might this impact on clinical practice or future developments? ► Individuals with lupus and these characteristics should be prioritised for close monitoring, counselled to receive vaccination, and receive preventive therapies if infected with SARS-CoV2. monotherapies with more intense immunosuppressive drugs (MMF, tacrolimus, cyclophosphamide, ciclosporin, azathioprine), biologic/targeted synthetic drug monotherapy and finally combination therapy with conventional and biologic diseasemodifying immunosuppressive drugs. GCs were categorised into four groups by dose: prednisone dose=0 mg/day, between 1 and 5 mg/day, between 6 and 9 mg/day and ≥10 mg/day. We used proportional odds logistic regression with severity as dependent variable, and covariates as described in the next paragraphs. This is similar to using binary logistic regression for each of the three possible dichotomisations of the four-category dependent variable, with the assumption that the OR is the same for each cut-off. The parallel lines test for proportional odds ordinal logistic regression confirmed that this assumption was not violated. Models included demographic variables and clinical characteristics as well as the time period in the pandemic during which the case was reported. Random effects were included for country and time. These variables were applied to capture the significant variability in regulations enforcing personal protective equipment, hospital resource allocation and quarantine procedures between countries and over the course of the pandemic. We assumed that missing data were 'missing at random' and missing data were handled using multiple imputation, with 50 imputed data sets. In all models, we included sex, age, region, GCs as a categorical variable (0, 1-5, 6-9, ≥10 mg/day), immunosuppressive medication category, time period and random effects of country and time. To assess the additional impact of comorbidities, we constructed an additional model that included the number of comorbidities and, separately, that included key comorbidities in SLE, including renal disease and hypertension/cardiovascular disease. Finally, we constructed a model that included the above variables but additionally included SLE disease activity. We conducted several additional analyses to examine associations of six medications of interest in SLE with COVID-19 outcomes: methotrexate (n=173), azathioprine (n=235), MMF (n=332), cyclophosphamide (n=29), rituximab (n=68) and belimumab (n=104). In these analyses, the drug of interest was excluded from the medication category of monotherapies with immunosuppressive drugs or from the biologics/targeted synthetic only category, and their effects were estimated separately. Four models were constructed for each medication: (1) unadjusted, (2) age-adjusted and sex-adjusted, (3) adjusted for age, sex, renal disease, hypertension/cardiovascular disease, comorbidity count, disease activity, region, time period and (4) confirmed cases (diagnosis made by PCR, antibody or antigen) adjusted for age, sex, renal disease, hypertension/cardiovascular disease, comorbidity count, disease activity, region and time period. Additionally, to evaluate the interaction between GC therapy and disease activity, an additional analysis was done adding this multiplicative interaction term. A sensitivity analysis combining mechanical ventilation or death in the highest category was also performed. Results were considered statistically significant using a twosided p<0.05. Analyses were conducted in R V.4.0.2 (R Core Team, 2020). Antimalarials were used as monotherapy by 665 individuals (34.6%), more intense immunosuppressive monotherapies (MMF, tacrolimus, cyclophosphamide, ciclosporin, azathioprine, with or without antimalarials) were used by 630 individuals (32.8%) at the time of COVID-19 onset. Two hundred and thirty (12.0%) individuals did not take immunosuppressive drugs or antimalarials. Eight hundred and forty-six (44.0%) individuals did not take prednisone, 467 (24.3%) individuals took between 1 and 5 mg/day, 78 (4.1%) individuals took between 6 and 9 mg/ day and 280 (14.6%) individuals took a dose ≥10 mg/day. Clinical outcomes, as well as outcomes as a function of treatment, for 1606 individuals were captured and are shown in table 2. The majority of individuals (69.6%) were not hospitalised. In the model including demographics, clinical characteristics, medications and disease activity, there were significant associations between demographic factors (older age, male sex, geographic location (being from outside of Europe, USA and Canada and Latin America), time period of the pandemic) and the ordinal severity outcome. Among comorbidities, chronic renal insufficiency or end-stage renal disease, hypertension/ cardiovascular disease and the number of other comorbidities were associated with more severe outcomes. GC use was also associated with more severe outcomes compared with those without GCs. Those who were not being treated for their SLE, or had moderate or high SLE disease activity also experienced more severe outcomes compared with those on remission (table 3) . These findings were consistent across various sensitivity analysis models (online supplemental table 1) . Finally, additional analyses were performed to assess the associations of methotrexate, azathioprine, MMF, cyclophosphamide, rituximab and belimumab separately with the ordinal severity outcome, demonstrating that there was no independent association of these drugs with the ordinal severity outcome in the fully adjusted model; however, rituximab was associated with poorer outcomes and belimumab with better outcomes in the unadjusted as well as the age-adjusted and sex-adjusted model, and MMF and cyclophosphamide were associated with poorer outcomes and methotrexate was associated with better outcomes only in the age-adjusted and sex-adjusted model (table 4) . There was no statistically significant interaction between GC dose and disease activity or between DMARD use and disease activity (data not shown). The results were nearly identical (online supplemental tables 2 and 3) in the alternative model in which mechanical ventilation and death were combined to constitute the highest category. During the COVID-19 pandemic, rheumatologists have been particularly concerned about individuals with SLE. These individuals are often significantly immunosuppressed, commonly use moderate or high doses of GCs and have a high comorbidity burden. Moreover, many types of immune dysregulation occur in SLE, including in the interferon pathway, which is critical to the innate immune response during SARS-CoV-2 infection. 16 However, SLE is a relatively uncommon disease and it has been difficult to accumulate a sufficient number of cases to examine risk factors for poor COVID-19 outcomes in this vulnerable population. Here, we report the largest study of SLE and COVID-19 to date. In our analyses of over 1600 cases, we found that the use of GCs, having untreated or active SLE, or using rituximab was associated with more severe COVID-19 outcomes. In addition to these factors specific to SLE, our findings also highlight that many factors associated with more severe COVID-19 outcomes in the general population are important in SLE, including male gender, 15 17 18 age 17-20 and comorbidity burden. [17] [18] [19] Prednisone use, even at relatively low doses of <5 mg/day, was associated with poorer outcomes in our analysis. In the C19-GRA registry, which included a wide array of rheumatic diseases, only prednisone at doses ≥10 mg/day was associated with hospitalisation or mortality. 4 13 Interestingly, in additional analyses of the registry we found that in the absence of disease activity, the relationship between GC and mortality diminished. 21 However, in SLE, even low doses of GCs were associated with more severe COVID-19 outcomes, including in those with low disease activity. Like our results, in a small study from Belgium, glucocorticoid dose was positively associated with a higher risk of hospitalisation in patients with SLE. 22 These findings suggest that GCs are of special concern during the pandemic for people with SLE. Our analyses also demonstrated that individuals not receiving treatment for their SLE at the time of COVID-19 diagnosis had poorer outcomes. The poor outcomes seen in this group may be multifactorial, and it is plausible that social risk factors play a role, such as lack of access to SLE care or treatment, or poor adherence with medications. Consistent with these results, individuals outside Europe, the USA and Canada had a poorer outcome, possibly related to healthcare access, but it was not statistically significant for Latin American individuals. Poverty and inequality have been associated with a higher risk and severity of COVID-19 globally, 14 23 and it is likely that health disparities in SLE may be exacerbated by the pandemic. Rituximab has been associated with poorer outcomes in patients with RA. 2 We also found this association in SLE in our analysis, but it was present only in the unadjusted and ageadjusted and sex-adjusted models; this may be due to the smaller number of individuals on rituximab in our study and resultantly low power in statistical analyses (n=68). In fully adjusted models (including confirmed cases and those diagnosed based on symptoms and epidemiological criteria), there was a trend for an association between rituximab and poorer outcomes. It is important to point out that in the age-adjusted and sex-adjusted models MMF, cyclophosphamide was associated with poorer outcomes. Cyclophosphamide was not evaluated in a fully adjusted model due to a small sample size. These findings are similar to what has been reported in other studies. For example, in a recent metaregression including several rheumatic diseases, GC use and immunosuppressive drugs use in monotherapy or combination were associated with hospitalisation and death from COVID-19. 24 Patients using belimumab generally had more favourable outcomes in our study; it is unclear if this may partly reflect confounding by healthcare access or socioeconomic status, as this drug is more commonly used in high-income nations. The association between methotrexate and better outcomes in the age-adjusted and sex-adjusted model could be related to a better disease activity control, as it did not remain significantly associated in the fully adjusted model. Because there were multiple comparisons, significance should be interpreted with caution. Given that there were six statistical comparisons made, one approach is to adjust the p value to a 0.01 level of significance. Using this more conservative approach, belimumab still remains statistically associated with less severe COVID-19 outcomes in the age-adjusted and sex-adjusted model. Previous investigators have found an association between SLE disease activity and serious infections. 25 It is likely that both underlying immune dysfunction and the use of immunosuppressive therapies increase the risk of infection in SLE, which would explain the association between SLE disease activity and the severity of SARS-CoV-2 infection reported here. The prognosis of patients with COVID-19 has improved over the course of the pandemic, which may be the result of many factors, including more widespread testing (leading to diagnosis of milder cases), improved pharmacological therapy and a better understanding of the timing, method of ventilatory support in critically ill patients and vaccination status for the most recent cases. Our findings suggest that patients with SLE diagnosed in later periods of the pandemic had better outcomes relative to the first part of the pandemic, which is consistent with the overall trends in the general population. 26 It is important to note that chronic kidney disease, a common and serious complication of SLE, has one of the strongest associations with poor COVID-19 outcomes. Chronic kidney disease is also an important risk factor for severe in the general population and may even pose a greater risk than the presence of diabetes. 27 In addition to renal disease, our findings indicate that other comorbidities also increase the risk of severe outcomes, which is consistent with numerous previous studies. 4 19 21 In SLE, medications, particularly GCs, can impact important comorbidities such as hypertension, diabetes or obesity, 28 which likely increases vulnerability to severe COVID-19 outcomes. Several limitations of this study should be noted. First, the C19-GRA is a registry that is predicated on physician reporting of COVID-19 in patients with rheumatic disease, and as such, may be skewed to include more severe COVID-19 cases. Patients with more severe COVID-19 are more likely to come to the attention of their rheumatology provider. Second, even though we were able to examine the relationship of several factors with more severe outcomes, we cannot exclude other confounders like access to healthcare or socioeconomic status. Third, although the physician global assessment is a valid, responsive and feasible instrument, given its less than optimal reliability it is not ideal to just assess it to the exclusion of the patient's assessment or other measures of disease activity; this is a limitation of our study. Finally, we were underpowered to look at some important treatments for SLE, such as cyclophosphamide, in our fully adjusted models; data on voclosporin and anifrolumab, two newly approved therapies for SLE, were not available in the registry at the time of our analyses. In conclusion, we found that in addition to age, male sex and comorbidities, the use of GCs and having untreated or active disease were associated with more severe COVID-19 outcomes in individuals with SLE. Individuals with these characteristics should be prioritised for close monitoring, counselled to receive vaccination and receive preventive therapies such as monoclonal antibodies (when available) if exposed to SARS-CoV-2. Ethics approval This study involves human participants but the UK Health Research Authority and the University of Manchester, as well as the University of California, San Francisco Institutional Review Board exempted this study. The C19-GRA physician-reported registry was defined as 'not human subjects research' by the UK Health Research Authority and the University of Manchester, as well as under US Federal Guidelines assessed by the University of California, San Francisco Institutional Review Board. Due to the de-identified and non-interventional nature of the study, it was determined to be exempt by each institutional review board. Provenance and peer review Not commissioned; externally peer reviewed. Data availability statement Data are available on reasonable request. Data are available on reasonable request. Applications to access the data should be made to the C19-GRA Steering Committee. Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. This article is made freely available for personal use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. Collaborators The COVID-19 Global Rheumatology Alliance (GRA): Brahim Dahou (Association Rhumatologues Algériens Privés Branimir Anić (Division of Clinical Immunology and Rheumatology Medipont plus s.ro Dimitrios Vassilopoulos (Hippokration General Hospital Isala Hospital Isala Hospital St James' Hospital County Emergency Hospital County Emergency Hospital Simona Rednic (County Emergency Hospital Sf Maria Clinical Hospital Faculty Hospital Poliklinika MarMedico, s.r.o Anna Sabová (súkromná reumatologická ambulancia Bakırköy Dr Sadi Konuk Research and Training Hospital Selda çelİk (Bakirkoy Dr Sadi Konuk Educational and Research Hospital Leeds Teaching Hospitals NHS Trust Sasha Dunt (Countess of Chester NHS Foundation Trust Lancashire and South Cumbria NHS Foundation Trust King's College Hospital King's College Hospital King's College Hospital Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Arthritis and Rheumatology Consultants Brigham and Women's Hospital, USA) Brigham and Women's Hospital, USA) Brigham and Women's Hospital, USA) Brigham and Women's Hospital, USA) Institute of Rheumatic and Autoimmune Diseases Suneya Hogarty (Integrative Arthritis and Pain Consultants Epidemiology of systemic lupus erythematosus Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry Age-Specific mortality and immunity patterns of SARS-CoV-2 Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus Patients with lupus with COVID-19: University of Michigan experience What is the true incidence of COVID-19 in patients with rheumatic diseases? COVID-19 and systemic lupus erythematosus: a case series Poor Prognosis of COVID-19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross-Sectional Population Study Of 252 119 Patients Incidence of COVID-19 hospitalisation in patients with systemic lupus erythematosus: a nationwide cohort study from Denmark The REDCap Consortium: building an international community of software platform partners Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry Association of race and ethnicity with COVID-19 outcomes in rheumatic disease: data from the COVID-19 global rheumatology alliance physician registry Dexamethasone in hospitalized patients with Covid-19 COVID-19 and systemic lupus erythematosus: focus on immune response and therapeutics Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) infection: a systematic review and metaanalysis of observational studies Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments Poverty, inequality and COVID-19: the forgotten vulnerable Response to: 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Lee Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multiethnic, multi-national Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions Acknowledgements We wish to thank all rheumatology providers who entered data into the registry.Competing interests MFU-G has received research grants from Pfizer and Janssen, not related to this manuscript. AD-G is supported by the Rheumatology Research Foundation (Scientist Development Award) and the Centers for Disease Control and Prevention. CR-S has received research grants from Janssen, not related to this manuscript. AEC has received consulting fees from AstraZeneca, BMS and GSK, all unrelated to this manuscript. LW has received consulting fees and speaker's honoraria from Aurinia Pharma unrelated to this manuscript. GJP-E reports no competing interests related to this work. Outside of this work, he reports personal consulting and/or speaking fees from Pfizer, GSK, Janssen and Sanofi (all